AVIRON
Form 425
January 09, 2002

Pursuant to Rule 4

MedImmune Registration Statement for Aviron Acquisition Declared Ef

Gaithersburg, MD, January 9, 2002 -- MedImmune, Inc. (Nasdaq: MEDI) announced today that the Secu
declared effective the registration statement MedImmune filed on December 10, 2001, as amended on
acquisition of Aviron (Nasdaq: AVIR). As previously announced, MedImmune and Aviron have entered
under which MedImmune will acquire Aviron through an exchange offer and merger transaction in whi
1.075 MedImmune shares for each Aviron share.

The exchange offer commenced on December 10, 2001 and is scheduled to expire at 12:00 midnight, N
9, 2002, unless extended. MedImmune expects to consummate the exchange offer at such time, subjec
conditions to the offer.

The Information Agent for the offer is MacKenzie Partners, Inc., 156 Fifth Avenue, New York, New
212-929-5500 or toll-free at 800-322-2885. The Dealer Manager for the offer is Merrill Lynch & Co
New York, New York 10080. Call collect at 609-274-3066.

Aviron is a biopharmaceutical company headquartered in Mountain View, California, focused on prev
innovative vaccine technologies. The company's product portfolio includes: FluMist , a live virus
mist for the prevention of influenza; a live parainfluenza virus type 3 vaccine; a vaccine to pre
cytomegalovirus vaccine. For more information on Aviron, visit the company's website at www.aviro

MedImmune, Inc. is a fully integrated biotechnology company focused on developing and marketing p
in areas such as infectious disease, immune regulation and cancer. Headquartered in Gaithersburg,
manufacturing facilities in Frederick, Maryland and Nijmegen, the Netherlands. MedImmune markets
Synagis® (palivizumab), which is marketed for the prevention of serious lower respiratory tract d
syncytial virus in pediatric patients at high risk of RSV disease, which is prominent in the Nort
through May (see full prescribing information at www.medimmune.com); Ethyol®, which is marketed f
cumulative renal toxicity associated with repeated administration of cisplatin in patients with a
cell lung cancer and moderate to severe xerostomia in patients undergoing post-operative radiatio
cancer, where the radiation port includes a substantial portion of the parotid (see full prescrib
www.medimmune.com); and CytoGam®, which is marketed for the prophylaxis against cytomegalovirus d
transplantation of kidney, lung, liver, pancreas, and heart (see full prescribing information at
has six products in various stages of clinical testing for a number of diseases and several more
testing. For more information on MedImmune, visit the company's website at www.medimmune.com.

This announcement may contain, in addition to historical information, certain forward-looking sta
uncertainties. Such statements reflect management's current views and are based on certain assump
materially from those currently anticipated as a result of a number of factors, including risks a
MedImmune's and Aviron's filings with the SEC. MedImmune and Aviron are developing products for p
can be no assurance that such development efforts will succeed, that such products will receive r
that, even if such regulatory clearance were received, such products would ultimately achieve com
assurance that the offer and merger will close or that Aviron will be integrated successfully or

We urge Aviron stockholders and other investors to read the registration statement on Form S-4, S
and other exchange offer documents which have been filed or will be filed by MedImmune with the S
and the related solicitation/recommendation statement filed by Aviron with the SEC. These documen
which should be read carefully before any decision is made with respect to the offer. Documents f
free at the SEC's website at www.sec.gov. Documents are also available for free from MacKenzie Pa